New blood pressure drug takes on amlodipine in overweight patients

NCT ID NCT07241338

Not yet recruiting Disease control Sponsor: Jing Liu Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a newer blood pressure drug, sacubitril/allisartan, to the standard drug amlodipine in 104 overweight or obese adults with high blood pressure. Participants will take one of the two drugs for 8 weeks, with dose adjustments if needed. The main goal is to see which drug lowers systolic blood pressure more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sacubitril/allisartan (a blood pressure drug) and amlodipine (a standard blood pressure drug)
What this could lead to
If it works, this could show that sacubitril/allisartan is a better option for controlling blood pressure in people who are overweight or obese.
What could go wrong
This is a small, early-phase trial with only 104 participants and an 8-week duration, so results may not apply to everyone. It is also open-label, meaning both doctors and patients know which drug is given, which can bias results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Peking University People's Hospital

    Beijing, China

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.